J.P. Morgan has published a research report on Medtronic (NYSE:

). In the report, J.P. Morgan wrote, "Medtronic reported largely in-line 1Q results this morning. Revenues of $4.049B grew 7.3% reported (+2.4% constant currency; +1.1% organic) and came in $70M above consensus and $15M below our estimate." J.P. Morgan rated Medtronic a Neutral with no price target given. Medtronic closed Monday at $31.18.